ArticleFrontiers in immunology2023
Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Efficacy of upadacitinib in palmoplantar pustulosis case series highlights the complex immune response patterns.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- Acquired perforating dermatosis associated with uremic pruritus treated with dupilumab monotherapy: A case report.JAAD case reports · 2026Article
- Acquired Reactive Perforating Collagenosis-A Rare Entity Occurring Within Common Disorders: A Systematic Review and Our Personal Experience.Journal of clinical medicine · 2026Review
- Apremilast for acquired reactive perforating collagenosis with metabolic and infectious comorbidities: a case report.Frontiers in immunology · 2026Article
- Dupilumab Can Be Effective for Immune-Related Adverse Event Dermatitis: A Case Report and Review of the Literature.Clinical, cosmetic and investigational dermatology · 2026Article
- Acquired Reactive Perforating Collagenosis Treated with Upadacitinib: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- Immune checkpoint inhibitor-associated acquired reactive perforating collagenosis treated with dupilumab.JAAD case reports · 2025Article
- The treatment for acquired reactive perforating collagenosis with abrocitinib: A case report.JAAD case reports · 2025Article
- Successful Nemolizumab Treatment of Refractory Acquired Reactive Perforating Collagenosis in a Diabetic Patient.Cureus · 2025Article
- Successful Treatment with Dupilumab of Acquired Reactive Perforating Collagenosis with End-stage Renal Disease.Acta dermato-venereologica · 2025Article
- Efficacy of Upadacitinib in the Treatment of Acquired Reactive Perforating Collagenosis in a Patient with Type 1 Diabetes: A Case Report and A Literature Review.Clinical, cosmetic and investigational dermatology · 2025Article
- A Case of Acquired Reactive Perforating Dermatosis with Complete Resolution of Eruptions on Upper and Lower Limbs During the Treatment of Diabetes Mellitus and Peripheral Artery Disease.Medicina (Kaunas, Lithuania) · 2024Article
- A potential new treatment with upadacitinib for acquired reactive perforating collagenosis.JAAD case reports · 2024Article
- Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report.Clinical, cosmetic and investigational dermatology · 2024Article
- Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired reactive perforating collagenosis (ARPC) is a clinically challenging disease with an unclear pathogenesis. Objective: To evaluate the efficacy and safety of dupilumab for the treatment of ARPC, and analyze the expression of type 2 inflammation-related molecules in ARPC lesions. Methods: This retrospective cohort study included 20 patients with ARPC; 10 received dupilumab and 10 received conventional therapy. The efficacy and safety of dupilumab were evaluated at 12 weeks. Immunohistochemical and immunofluorescence analyses of T- and B-cell markers, and type 2 inflammation-related cytokines, were performed on skin samples from ARPC patients, atopic dermatitis (AD) patients, and healthy controls. Results: Significantly more patients showed improvements in the Investigator Global Assessment score (100% vs. 0%; p < 0.0001) and itching (90%/8.33%, P =.001) in the dupilumab group compared to the conventional group at 12 weeks. There were no adverse effects in the dupilumab group. The ARPC lesions showed enhanced dermal infiltration of CD3+ T-cells, with a predominance of Th2 cells, similar to AD lesions. IL-4 and IL-13 were co-localized with GATA3 in ARPC lesions. Conclusion: Dupilumab improved ARPC charaterized with type 2 inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.